0001729427 2026-01-01 2026-06-30 0001729427 2026-08-11 0001729427 2026-06-30 0001729427 2025-12-31 0001729427 2026-04-01 2026-06-30 0001729427 2025-04-01 2025-06-30 0001729427 2025-01-01 2025-06-30 0001729427 us-gaap:CommonStockMember 2024-12-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001729427 us-gaap:RetainedEarningsMember 2024-12-31 0001729427 2024-12-31 0001729427 us-gaap:CommonStockMember 2025-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001729427 us-gaap:RetainedEarningsMember 2025-03-31 0001729427 2025-03-31 0001729427 us-gaap:CommonStockMember 2025-12-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001729427 us-gaap:RetainedEarningsMember 2025-12-31 0001729427 us-gaap:CommonStockMember 2026-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001729427 us-gaap:RetainedEarningsMember 2026-03-31 0001729427 2026-03-31 0001729427 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001729427 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001729427 2025-01-01 2025-03-31 0001729427 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001729427 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001729427 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001729427 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001729427 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001729427 2026-01-01 2026-03-31 0001729427 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001729427 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001729427 us-gaap:CommonStockMember 2025-06-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001729427 us-gaap:RetainedEarningsMember 2025-06-30 0001729427 2025-06-30 0001729427 us-gaap:CommonStockMember 2026-06-30 0001729427 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001729427 us-gaap:RetainedEarningsMember 2026-06-30 0001729427 2026-05-02 2026-05-05 0001729427 us-gaap:ComputerEquipmentMember 2026-06-30 0001729427 us-gaap:MachineryAndEquipmentMember 2026-06-30 0001729427 us-gaap:FurnitureAndFixturesMember 2026-06-30 0001729427 CNSP:November2025NoteMember 2025-11-08 0001729427 CNSP:November2025NoteMember 2025-11-07 2025-11-08 0001729427 us-gaap:CommonStockMember 2024-05-01 0001729427 us-gaap:CommonStockMember 2026-06-30 0001729427 us-gaap:CommonStockMember 2025-07-20 2025-07-22 0001729427 2025-07-21 0001729427 2025-07-22 0001729427 2025-11-19 0001729427 2025-11-20 0001729427 us-gaap:PrivatePlacementMember CNSP:SecuritiesPurchaseAgreementMember 2026-05-03 2026-05-04 0001729427 CNSP:PreFundedWarrantsMember us-gaap:PrivatePlacementMember CNSP:SecuritiesPurchaseAgreementMember 2026-05-04 0001729427 CNSP:PreFundedWarrantsMember CNSP:SecuritiesPurchaseAgreementMember 2026-05-03 2026-05-04 0001729427 CNSP:PreFundedWarrantsMember CNSP:SecuritiesPurchaseAgreementMember 2026-06-30 0001729427 us-gaap:CommonStockMember CNSP:May2025PlacementAgencyAgreementMember 2025-05-12 2025-05-13 0001729427 CNSP:PreFundedAGPWarrantsMember CNSP:May2025PlacementAgencyAgreementMember 2025-05-12 2025-05-13 0001729427 CNSP:SeriesFWarrantsMember CNSP:May2025PlacementAgencyAgreementMember 2025-05-12 2025-05-13 0001729427 CNSP:Plan2020Member 2023-08-08 2023-08-09 0001729427 CNSP:Plan2020Member 2025-11-15 2026-11-16 0001729427 CNSP:Plan2020Member 2025-11-17 0001729427 CNSP:Plan2020Member 2026-06-30 0001729427 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-06-30 0001729427 us-gaap:EmployeeStockOptionMember 2026-06-30 0001729427 CNSP:WarrantsMember 2026-01-01 2026-06-30 0001729427 CNSP:WarrantsMember 2026-06-30 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2026-06-30 0001729427 CNSP:PerformanceUnitsMember 2026-06-30 0001729427 CNSP:PurchaseAgreementMember 2026-01-01 2026-06-30 0001729427 CNSP:PurchaseAgreementMember 2025-01-01 2025-06-30 0001729427 CNSP:PreFundedWarrantsMember 2026-01-01 2026-06-30 0001729427 CNSP:PreFundedWarrantsMember 2025-01-01 2025-06-30 0001729427 CNSP:AGPATMSalesAgreementMember 2026-01-01 2026-06-30 0001729427 CNSP:AGPATMSalesAgreementMember 2025-01-01 2025-06-30 0001729427 CNSP:CommonStockAndCommonWarrantMember 2026-01-01 2026-06-30 0001729427 CNSP:CommonStockAndCommonWarrantMember 2025-01-01 2025-06-30 0001729427 CNSP:CommonStockAndPreFundedAGPWarrantsMember 2026-01-01 2026-06-30 0001729427 CNSP:CommonStockAndPreFundedAGPWarrantsMember 2025-01-01 2025-06-30 0001729427 CNSP:TotalCommonStockAndPrefundedWarrantsMember 2026-01-01 2026-06-30 0001729427 CNSP:TotalCommonStockAndPrefundedWarrantsMember 2025-01-01 2025-06-30 0001729427 us-gaap:EmployeeStockOptionMember 2025-12-31 0001729427 CNSP:WarrantsMember 2025-12-31 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-06-30 0001729427 CNSP:PerformanceUnitsMember 2025-12-31 0001729427 CNSP:PerformanceUnitsMember 2026-01-01 2026-06-30 0001729427 us-gaap:StockOptionMember 2026-04-01 2026-06-30 0001729427 us-gaap:StockOptionMember 2025-04-01 2025-06-30 0001729427 us-gaap:StockOptionMember 2026-01-01 2026-06-30 0001729427 us-gaap:StockOptionMember 2025-01-01 2025-06-30 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2026-04-01 2026-06-30 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2025-04-01 2025-06-30 0001729427 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001729427 CNSP:MrClimacoMember 2025-12-16 0001729427 CNSP:ReataAgreementMember 2017-11-21 0001729427 us-gaap:CommonStockMember CNSP:CorticeAgreementsMember CNSP:ClosingOfTheTransactionMember 2024-07-28 2024-07-29 0001729427 us-gaap:CommonStockMember CNSP:CorticeAgreementsMember CNSP:NasdaqRequiredShareholderApprovalMember 2024-07-28 2024-07-29 0001729427 us-gaap:WarrantMember 2026-04-01 2026-06-30 0001729427 us-gaap:WarrantMember 2025-04-01 2025-06-30 0001729427 us-gaap:WarrantMember 2026-01-01 2026-06-30 0001729427 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001729427 us-gaap:StockOptionMember 2026-04-01 2026-06-30 0001729427 us-gaap:StockOptionMember 2025-04-01 2025-06-30 0001729427 us-gaap:StockOptionMember 2026-01-01 2026-06-30 0001729427 us-gaap:StockOptionMember 2025-01-01 2025-06-30 0001729427 us-gaap:PerformanceSharesMember 2026-04-01 2026-06-30 0001729427 us-gaap:PerformanceSharesMember 2025-04-01 2025-06-30 0001729427 us-gaap:PerformanceSharesMember 2026-01-01 2026-06-30 0001729427 us-gaap:PerformanceSharesMember 2025-01-01 2025-06-30 0001729427 CNSP:PreFundedWarrantsMember 2026-06-30 0001729427 CNSP:BankDepositAccountMember 2026-06-30 0001729427 CNSP:BankDepositAccountMember us-gaap:FairValueInputsLevel1Member 2026-06-30 0001729427 CNSP:BankDepositAccountMember us-gaap:FairValueInputsLevel2Member 2026-06-30 0001729427 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2026-06-30 0001729427 CNSP:BankDepositAccountMember 2025-12-31 0001729427 CNSP:BankDepositAccountMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0001729427 CNSP:BankDepositAccountMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0001729427 CNSP:BankDepositAccountMember us-gaap:FairValueInputsLevel3Member 2025-12-31 iso4217:USD shares iso4217:USD shares pure CNSP:Integer false --12-31 2026 Q2 0001729427 -7525000 -8188000 1 1 10-Q true 2026-06-30 false 001-39126 CNS Pharmaceuticals, Inc. NV 82-2318545 2100 West Loop South Suite 900 Houston TX 77027 800 946-9185 Common Stock CNSP NASDAQ Yes Yes Non-accelerated Filer true false false 1461449 19985000 7201000 73000 45000 1865000 856000 21923000 8102000 0 503000 15000 18000 15000 521000 21938000 8623000 3738000 3772000 0 328000 3738000 4100000 3738000 4100000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 0.001 0.001 300000000 300000000 1461449 1461449 632516 632516 2000 1000 125998000 104797000 -107800000 -100275000 18200000 4523000 21938000 8623000 1201000 1167000 4745000 4410000 1499000 1242000 2930000 2337000 2700000 2409000 7675000 6747000 -2700000 -2409000 -7675000 -6747000 116000 38000 160000 81000 4000 4000 10000 10000 112000 34000 150000 71000 -2588000 -2375000 -7525000 -6676000 -0.38 -6.42 -1.99 -22.35 -0.38 -6.42 -1.99 -22.35 6838205 370127 3773970 298776 6838205 370127 3773970 298776 117796 0 90601000 -84424000 6177000 127582 9033000 9033000 13 1000 1000 62000 62000 -4301000 -4301000 245365 0 99695000 -88725000 10970000 27084 4505000 4505000 231964 3000 3000 22000 22000 -2375000 -2375000 504413 0 104225000 -91100000 13125000 632516 1000 104797000 -100275000 4523000 178933 482000 482000 3000 3000 -4937000 -4937000 811449 1000 105282000 -105212000 71000 650000 1000 20714000 20715000 2000 2000 -2588000 -2588000 1461449 2000 125998000 -107800000 18200000 -7525000 -6676000 5000 84000 13000 2000 647000 1061000 -34000 -935000 -8188000 -8586000 10000 -0 -10000 0 46000 -0 187000 176000 7000 3000 -0 1000 0 883000 21208000 13545000 20982000 14254000 12784000 5668000 7201000 6461000 19985000 12129000 10000 10000 0 0 0 31000 18000 6000 <p id="xdx_80D_eus-gaap--NatureOfOperations_z1BQRNBG9qs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – <span id="xdx_821_zlBGHIgyxY3d">Nature of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CNS Pharmaceuticals, Inc. (“we”, “our”, the “Company”) is a biotechnology company organized as a Nevada corporation in July 2017. In March 2026, the Company announced a new corporate strategy focused on developing innovative therapies for serious diseases. The Company is leveraging its executive team’s multi-functional experiences across high-value therapeutic areas to execute its new corporate strategy, which also includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets TPI 287 and Berubicin for which the Company has intellectual property rights under license agreement with Cortice and owns pursuant to a collaboration and asset purchase agreement with Reata.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zrk7iEGPG5Tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 – <span id="xdx_82A_zH9xD7ejgX1f">Summary of Significant Accounting Policies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zupuDkJKxzBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_866_zLNWufC42WHb">Basis of Presentation</span> </b>- The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim unaudited financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited financial statements include all adjustments (consisting of normal recurring adjustments) which are, in the opinion of the Company, necessary in order to make the condensed financial statements not misleading. Operating results for the six months ended June 30, 2026 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2026. For more complete financial information, these unaudited financial statements should be read in conjunction with the audited financial statements for the period ended December 31, 2025 included in our Form 10-K filed with the SEC on March 31, 2026 (“Form 10-K”). Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_844_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zUbhdfEk7kA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_864_zvDiGKcRKh71">Liquidity and Going Concern</span> - </b>Since inception, the Company has a history of net losses and negative cash flows from operations. For the six months ended June 30, 2026, the Company recorded a net loss of approximately $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn3n3_dixL_c20260101__20260630_zVLbJ6huSQi" title="Net loss::XDX::7525"><span style="-sec-ix-hidden: xdx2ixbrl0433">7.5</span></span> million and used cash in operations of approximately $<span id="xdx_904_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_dixL_c20260101__20260630_z3JxAOiWEcx2" title="Net cash used in operating activities::XDX::8188"><span style="-sec-ix-hidden: xdx2ixbrl0435">8.2</span></span> million. As of June 30, 2026, the Company had an accumulated deficit of approximately $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20260630_zRPQx6iyj8pb" title="Accumulated deficit">107.8</span> million and cash of approximately $<span id="xdx_90C_eus-gaap--Cash_iI_pn6n6_c20260630_zjnd03ZIXmkd" title="Cash">20</span>.0 million. On May 5, 2026, the Company completed a private placement financing resulting in gross proceeds of approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20260502__20260505_zl72fZWardpi" title="Proceeds from private placement financing">22.5</span> million (see Note 4 – Equity). The Company believes that the net proceeds from this financing, combined with the Company's existing cash resources, are sufficient to fund planned operations beyond twelve months from the date these financial statements are issued. Accordingly, these financial statements have been prepared assuming the Company will continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zgoEo2rwqkV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_86D_zzsQ4llnb0Ia"><b>Cash and Cash Equivalents</b></span><b> -</b> The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $250,000. The Company did not carry any cash balances in excess of the FDIC limit as of June 30, 2026. The Company has not experienced losses on these accounts and it believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zjiw7Ss4CG77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_865_zAQjpKckSyt8">Property and Equipment</span> -</b> Property and equipment is recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfEstimatedUsefulLivesTableTextBlock_zKnFjcwuVZY1" style="width: 100%; border-collapse: collapse; font-size: 10pt" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Estimated useful lives)"> <tr style="vertical-align: top"> <td><span id="xdx_8B3_zQj4kigvYRM5" style="display: none">Schedule of estimated useful lives</span></td> <td> </td></tr> <tr style="vertical-align: top"> <td style="border: black 1pt solid; width: 33%"><span style="font-size: 10pt"><b>Leasehold improvement</b></span></td> <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 67%"><span style="font-size: 10pt"><b>Shorter of estimated useful lives or the term of the lease</b></span></td></tr> <tr style="vertical-align: top; background-color: #EEEEEE"> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Computer equipment</span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpINX7A8Og0g" title="Estimated useful Life">3</span> years</span></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Machinery and equipment</span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zSKPQF2bbyU8" title="Estimated useful Life">5</span> years</span></td></tr> <tr style="vertical-align: top; background-color: #EEEEEE"> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Furniture and office equipment</span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zkMvwQA5TXc3" title="Estimated useful Life">7</span> years</span></td></tr> </table> <p id="xdx_8AD_zj3oCUncCIAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Repairs and maintenance costs are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p id="xdx_847_ecustom--RelatedPartyTransactionsPolicyTextBlock_zyTz3pzZ4HGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zNAU7JesfyZ9">Related Parties</span> - </b>The Company follows Accounting Standards Codification (“ASC”) 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zTH0uJyNNJEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86F_z2LNS4m5Vnr1">Stock-based Compensation</span> -</b> Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period for stock options and restricted stock units.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84B_ecustom--RestrictedStockUnitsPolicyTextBlock_zhHVizlu132b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_864_zTgr9xPPO0l1">Restricted Stock Units (“RSUs”)</span></b> - Our RSUs vest over two to four years from the date of grant. The fair value of RSUs is the market price of our common stock at the date of grant. The Company reverses any previously recognized compensation cost associated with forfeited RSUs in the period which the forfeiture occurs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_846_ecustom--PerformanceUnitsPolicyTextBlock_zPSf6GzcZe8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_864_zWGN1gP4ZyE6">Performance Units (“PUs”)</span></b> - The PUs vest based on our performance against predefined share price targets and the achievement of Positive Interim Clinical Data as defined by the Board.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_846_ecustom--WarrantsPolicyPolicyTextBlock_zRHA4pORGoYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_863_znnu8593yh53">Warrants</span> - </b>The Company evaluates all freestanding and embedded warrants to determine whether they meet the criteria for equity classification under ASC 815-40, <i>Derivatives and Hedging—Contracts in Entity’s Own Equity</i>, or if they must be classified as liabilities under ASC 480 or ASC 815-10. The Company evaluated the warrants and concluded they are indexed to the Company's common stock and meet the equity classification criteria under ASC 815-40, as they are settleable in shares and the Company has sufficient shares authorized. The warrants were recorded at fair value upon issuance within stockholders' equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_z9vokq3wgRb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_862_zvwXJak0dog5">Loss Per Common Share</span> </b>- Basic loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zCXian84aqU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_zPn0UQtNfHgk">Segment Reporting</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company manages its operations as a single segment for the purpose of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company using information about combined net loss from operations. All significant operating decisions are based upon an analysis of the Company as <span id="xdx_906_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20260101__20260630_zHFFpLQ9qBCi" title="Number of operating segment::XDX::1"><span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20260101__20260630_zDBoPXnqKtK7" title="Number of reporting segment::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0475"><span style="-sec-ix-hidden: xdx2ixbrl0477">one</span></span></span></span> operating segment, which is the same as its reporting segment. See statement of operations for information about combined net loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zupuDkJKxzBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_866_zLNWufC42WHb">Basis of Presentation</span> </b>- The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim unaudited financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited financial statements include all adjustments (consisting of normal recurring adjustments) which are, in the opinion of the Company, necessary in order to make the condensed financial statements not misleading. Operating results for the six months ended June 30, 2026 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2026. For more complete financial information, these unaudited financial statements should be read in conjunction with the audited financial statements for the period ended December 31, 2025 included in our Form 10-K filed with the SEC on March 31, 2026 (“Form 10-K”). Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_844_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zUbhdfEk7kA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_864_zvDiGKcRKh71">Liquidity and Going Concern</span> - </b>Since inception, the Company has a history of net losses and negative cash flows from operations. For the six months ended June 30, 2026, the Company recorded a net loss of approximately $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn3n3_dixL_c20260101__20260630_zVLbJ6huSQi" title="Net loss::XDX::7525"><span style="-sec-ix-hidden: xdx2ixbrl0433">7.5</span></span> million and used cash in operations of approximately $<span id="xdx_904_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_dixL_c20260101__20260630_z3JxAOiWEcx2" title="Net cash used in operating activities::XDX::8188"><span style="-sec-ix-hidden: xdx2ixbrl0435">8.2</span></span> million. As of June 30, 2026, the Company had an accumulated deficit of approximately $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20260630_zRPQx6iyj8pb" title="Accumulated deficit">107.8</span> million and cash of approximately $<span id="xdx_90C_eus-gaap--Cash_iI_pn6n6_c20260630_zjnd03ZIXmkd" title="Cash">20</span>.0 million. On May 5, 2026, the Company completed a private placement financing resulting in gross proceeds of approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20260502__20260505_zl72fZWardpi" title="Proceeds from private placement financing">22.5</span> million (see Note 4 – Equity). The Company believes that the net proceeds from this financing, combined with the Company's existing cash resources, are sufficient to fund planned operations beyond twelve months from the date these financial statements are issued. Accordingly, these financial statements have been prepared assuming the Company will continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> -107800000 20000000 22500000 <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zgoEo2rwqkV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_86D_zzsQ4llnb0Ia"><b>Cash and Cash Equivalents</b></span><b> -</b> The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $250,000. The Company did not carry any cash balances in excess of the FDIC limit as of June 30, 2026. The Company has not experienced losses on these accounts and it believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zjiw7Ss4CG77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_865_zAQjpKckSyt8">Property and Equipment</span> -</b> Property and equipment is recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfEstimatedUsefulLivesTableTextBlock_zKnFjcwuVZY1" style="width: 100%; border-collapse: collapse; font-size: 10pt" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Estimated useful lives)"> <tr style="vertical-align: top"> <td><span id="xdx_8B3_zQj4kigvYRM5" style="display: none">Schedule of estimated useful lives</span></td> <td> </td></tr> <tr style="vertical-align: top"> <td style="border: black 1pt solid; width: 33%"><span style="font-size: 10pt"><b>Leasehold improvement</b></span></td> <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 67%"><span style="font-size: 10pt"><b>Shorter of estimated useful lives or the term of the lease</b></span></td></tr> <tr style="vertical-align: top; background-color: #EEEEEE"> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Computer equipment</span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpINX7A8Og0g" title="Estimated useful Life">3</span> years</span></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Machinery and equipment</span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zSKPQF2bbyU8" title="Estimated useful Life">5</span> years</span></td></tr> <tr style="vertical-align: top; background-color: #EEEEEE"> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Furniture and office equipment</span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zkMvwQA5TXc3" title="Estimated useful Life">7</span> years</span></td></tr> </table> <p id="xdx_8AD_zj3oCUncCIAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Repairs and maintenance costs are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfEstimatedUsefulLivesTableTextBlock_zKnFjcwuVZY1" style="width: 100%; border-collapse: collapse; font-size: 10pt" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Estimated useful lives)"> <tr style="vertical-align: top"> <td><span id="xdx_8B3_zQj4kigvYRM5" style="display: none">Schedule of estimated useful lives</span></td> <td> </td></tr> <tr style="vertical-align: top"> <td style="border: black 1pt solid; width: 33%"><span style="font-size: 10pt"><b>Leasehold improvement</b></span></td> <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 67%"><span style="font-size: 10pt"><b>Shorter of estimated useful lives or the term of the lease</b></span></td></tr> <tr style="vertical-align: top; background-color: #EEEEEE"> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Computer equipment</span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpINX7A8Og0g" title="Estimated useful Life">3</span> years</span></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Machinery and equipment</span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zSKPQF2bbyU8" title="Estimated useful Life">5</span> years</span></td></tr> <tr style="vertical-align: top; background-color: #EEEEEE"> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Furniture and office equipment</span></td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zkMvwQA5TXc3" title="Estimated useful Life">7</span> years</span></td></tr> </table> P3Y P5Y P7Y <p id="xdx_847_ecustom--RelatedPartyTransactionsPolicyTextBlock_zyTz3pzZ4HGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zNAU7JesfyZ9">Related Parties</span> - </b>The Company follows Accounting Standards Codification (“ASC”) 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zTH0uJyNNJEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86F_z2LNS4m5Vnr1">Stock-based Compensation</span> -</b> Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period for stock options and restricted stock units.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84B_ecustom--RestrictedStockUnitsPolicyTextBlock_zhHVizlu132b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_864_zTgr9xPPO0l1">Restricted Stock Units (“RSUs”)</span></b> - Our RSUs vest over two to four years from the date of grant. The fair value of RSUs is the market price of our common stock at the date of grant. The Company reverses any previously recognized compensation cost associated with forfeited RSUs in the period which the forfeiture occurs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_846_ecustom--PerformanceUnitsPolicyTextBlock_zPSf6GzcZe8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_864_zWGN1gP4ZyE6">Performance Units (“PUs”)</span></b> - The PUs vest based on our performance against predefined share price targets and the achievement of Positive Interim Clinical Data as defined by the Board.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_846_ecustom--WarrantsPolicyPolicyTextBlock_zRHA4pORGoYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_863_znnu8593yh53">Warrants</span> - </b>The Company evaluates all freestanding and embedded warrants to determine whether they meet the criteria for equity classification under ASC 815-40, <i>Derivatives and Hedging—Contracts in Entity’s Own Equity</i>, or if they must be classified as liabilities under ASC 480 or ASC 815-10. The Company evaluated the warrants and concluded they are indexed to the Company's common stock and meet the equity classification criteria under ASC 815-40, as they are settleable in shares and the Company has sufficient shares authorized. The warrants were recorded at fair value upon issuance within stockholders' equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_z9vokq3wgRb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_862_zvwXJak0dog5">Loss Per Common Share</span> </b>- Basic loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zCXian84aqU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_zPn0UQtNfHgk">Segment Reporting</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company manages its operations as a single segment for the purpose of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company using information about combined net loss from operations. All significant operating decisions are based upon an analysis of the Company as <span id="xdx_906_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20260101__20260630_zHFFpLQ9qBCi" title="Number of operating segment::XDX::1"><span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20260101__20260630_zDBoPXnqKtK7" title="Number of reporting segment::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0475"><span style="-sec-ix-hidden: xdx2ixbrl0477">one</span></span></span></span> operating segment, which is the same as its reporting segment. See statement of operations for information about combined net loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_z03RGesAeuhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 3 – <span id="xdx_828_zbsnbP6XRsz3">Note Payable</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 8, 2025, the Company entered into a short-term note payable for an aggregate of $<span id="xdx_90B_eus-gaap--ShortTermBorrowings_iI_pn5n6_c20251108__us-gaap--ShortTermDebtTypeAxis__custom--November2025NoteMember_zKGONhApbJn" title="Short-term note payable">0.4</span> million, bearing interest at <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20251107__20251108__us-gaap--ShortTermDebtTypeAxis__custom--November2025NoteMember_zLY6gnj78695" title="Interest rate">8.24</span>% per year to finance certain insurance policies. Principal and interest payments related to the note will be repaid over an 11-month period with the final payment due on <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20251107__20251108__us-gaap--ShortTermDebtTypeAxis__custom--November2025NoteMember_zOEirKROo5me" title="Maturity date">October 8, 2026</span>. As of June 30, 2026 and December 31, 2025, the Company’s note payable balance was de minimis and $<span id="xdx_908_eus-gaap--NotesPayable_iI_pn5n6_c20260630_zpwwRMsERJ3d" title="Note payable balance"><span id="xdx_906_eus-gaap--NotesPayable_iI_pn5n6_c20251231_zlKL64Gtcye8" title="Note payable balance">0.3</span></span> million, respectively. On May 15, 2026, the Company terminated certain insurance policies that were financed by the short-term note payable and was issued a return of the premium that was financed by its short-term note payable, which resulted in a de minimis balance related to other insurance policies financed by the short-term note payable as of June 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> 400000 0.0824 2026-10-08 300000 300000 <p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z8Re08zTKhnl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 – <span id="xdx_824_zELmksMahjT2">Equity</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has authorized <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20240501__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zRt51os4RqJg">300,000,000</span> shares of common stock having a par value of $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zegBv7ArK0d2" title="Common stock, per value">0.001</span> per share. In addition, the Company authorized <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20260630_zw8zqvEcsQXa">5,000,000</span> shares of preferred stock to be issued having a par value of $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260630_z7NU7hCKJo4k" title="Preferred stock, par value">0.001</span>. The specific rights of the preferred stock shall be determined by the board of directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 22, 2025, the Company effected a reverse stock split on a <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20250720__20250722__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zevMRLMS01wh" title="Reverse stock split">1-for-12</span> basis without any change in the par value per share, which remained at $0.001. The reverse stock split has been retroactively adjusted throughout these financial statements and footnotes. The number of authorized shares of common stock was proportionately reduced from <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20250721_zoCQee5QZqn4" title="Common stock authorized">300,000,000</span> to <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20250722_zfi88ZMyPYwf" title="Common stock, shares authorized">25,000,000</span>, while the number of authorized shares of preferred stock was proportionately reduced from <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20250721_z4r6AFzfjEH6" title="Preferred stock authorized">5,000,000</span> to <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20250722_zecifz21Sgo4" title="Preferred stock, shares authorized">416,667</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 20, 2025, following approval by shareholders, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to increase the number of the Company’s authorized shares of common stock from <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20251119_zXN7MTk41TT" title="Common stock authorized">25,000,000</span> shares to <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20251120_zl2CHARkD9Dl" title="Common stock, shares authorized">300,000,000</span> shares and to increase the total number of authorized shares of preferred stock from <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20251119_zhX0eQ1Kobbb" title="Preferred stock authorized">416,667</span> shares to <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20251120_z0zMmxEr3WD6" title="Preferred stock, shares authorized">5,000,000</span> shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Common Stock and Pre-Funded Warrants</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 4, 2026, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Investors purchased in a private placement: (i) <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260503__20260504__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zFK5aLNyHMlf" title="Common stock issued shares">650,000</span> shares of the Company’s common stock at a purchase price of $2.30 per share; and (ii) pre-funded warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260504__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zm2LexAj5hbl" title="Warrants issued, shares">9,143,479</span> shares of common stock (the “Pre-Funded Warrants”) at a purchase price of $2.299 per Pre-Funded Warrant (the “Offering”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to certain ownership limitations, the Pre-Funded Warrants are exercisable immediately upon issuance into one share of common stock at an exercise price per share of $0.001 (as adjusted from time to time in accordance with the terms thereof) and expire once such Pre-Funded Warrant is fully exercised. The holder of a Pre-Funded Warrant is prohibited from exercising any Pre-Funded Warrants to the extent that such exercise would result in the number of shares of common stock beneficially owned by such holder and its affiliates exceeding 4.99% (or 9.99% as applicable) of the total number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder’s election not to exceed 9.99%. The gross proceeds to the Company from the Offering were approximately $<span id="xdx_904_ecustom--GrossProceedsPrivatePlacementFinancing_pn5n6_c20260503__20260504__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zAb3s8WY4lX5" title="Gross proceeds">22.5</span> million. Net proceeds, after deducting commissions and other offering expenses, were $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20260503__20260504__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z5qh1TXdNSH5" title="Net proceeds">20.7</span> million. As of June 30, 2026, <span id="xdx_902_ecustom--WarrantsExercisedShares_iI_pip0_do_c20260630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zaPjHJFJLKD1" title="Warrants exercised, shares">no</span> Investors have exercised their Pre-Funded Warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 26, 2024, the Company entered into a Sales Agreement (the “AGP ATM Sales Agreement”) with A.G.P./Alliance Global Partners (“AGP”). Pursuant to the terms of the AGP ATM Sales Agreement, the Company originally was permitted to sell from time to time through AGP, as sales agent or principal, shares of the Company’s common stock with initial aggregate sales price of up to $5.2 million. On July 30, 2024, the Company increased the aggregate sales price of common stock that may be sold under the AGP ATM Sales Agreement to $25.0 million (not including the original $5.2 million). On March 20, 2025, the Company increased the aggregate sales price of common stock that may be sold under the AGP ATM Sales Agreement to $43.5 million (which amount includes $6.4 million remaining from the $30.2 million set forth above). On September 19, 2025, the Company decreased the sales price of common shares that may be sold under the AGP ATM Sales Agreement to $1.8 million, which amount does not include any shares of common stock sold prior to such date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 13, 2025, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”) for the public offering by the Company of (i) <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250512__20250513__us-gaap--SubsidiarySaleOfStockAxis__custom--May2025PlacementAgencyAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zAzg55Nls836" title="Stock issued new, shares">27,084</span> shares of the Company’s common stock, (ii) pre-funded warrants to purchase <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250512__20250513__us-gaap--SubsidiarySaleOfStockAxis__custom--May2025PlacementAgencyAgreementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedAGPWarrantsMember_z7SRLdaD69Z5" title="Stock issued new, shares">302,295</span> shares of common stock (the “Pre-Funded A.G.P. Warrants”); and (iii) Series F Warrants to purchase up to an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250512__20250513__us-gaap--SubsidiarySaleOfStockAxis__custom--May2025PlacementAgencyAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFWarrantsMember_zGv6wsOrHQKf" title="Stock issued new, shares">329,381</span> shares of common stock (the “Common Warrants”). The Common Warrants and Pre-Funded A.G.P. Warrants are collectively referred to herein as the (“Warrants”). The combined purchase price of one share of common stock and one accompanying Common Warrant was $15.18 and the combined purchase price of one Pre-Funded A.G.P. Warrant and one accompanying Common Warrant was $15.17.<b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to certain ownership limitations, the Warrants are exercisable immediately upon issuance. Each Pre-Funded A.G.P. Warrant is exercisable into one share of common stock at a price per share of $0.001 and expire once such Pre-Funded A.G.P. Warrants are fully exercised. The Common Warrants are exercisable into one share of Common Stock at a price per share of $13.68 and expire five years from Initial Exercise Date. The closing of this offering occurred on May 14, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the common stock and pre-funded warrant activity for the six months ended June 30, 2026 and 2025 (in thousands, except share amounts):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfProductWarrantyLiabilityTableTextBlock_pn3n3_zOGBKlbMDaA8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details - Pre-funded warrant activity)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BB_zfIdmGxNC6Wg" style="display: none">Schedule of pre funded warrant activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 32%; text-align: left">Purchase Agreement</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20260101__20260630__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zJuMI51Wpl3h" style="width: 13%; text-align: right" title="Stock issued new, shares">650,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20260101__20260630__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zfi3WA7DyvZf" style="width: 13%; text-align: right" title="Stock issued new, value">1,495</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_d0_c20250101__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zdZxeQd5Ilfk" style="width: 13%; text-align: right" title="Stock issued new, shares">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_d0_c20250101__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zV3ZZkFrgc0l" style="width: 13%; text-align: right" title="Stock issued new, value">–</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Pre-Funded Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_z2kvHWihHHNa" style="text-align: right">9,143,479</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zoum93O3ukIj" style="text-align: right">21,021</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zqiyiMBp0Z33" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_z3qPQz239dyc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0553">–</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">AGP ATM Sales Agreement</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20260101__20260630__us-gaap--SubsidiarySaleOfStockAxis__custom--AGPATMSalesAgreementMember_z3mazfSxVyP8" style="text-align: right" title="Stock issued new, shares">178,933</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20260101__20260630__us-gaap--SubsidiarySaleOfStockAxis__custom--AGPATMSalesAgreementMember_zMBSVU6w89F7" style="text-align: right" title="Stock issued new, shares">501</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20250101__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--AGPATMSalesAgreementMember_zQT2Vc0vowI6" style="text-align: right" title="Stock issued new, shares">127,582</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250101__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--AGPATMSalesAgreementMember_zHBfoMCv5xG9" style="text-align: right" title="Stock issued new, shares">9,033</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Common stock and Common Warrant</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_d0_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndCommonWarrantMember_zyOayAuK8Lnd" style="text-align: right" title="Stock issued new, shares">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_d0_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndCommonWarrantMember_z1Bu5GiKcNC5" style="text-align: right" title="Stock issued new, value">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_d0_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndCommonWarrantMember_zdsUqN2Bq9v5" style="text-align: right" title="Stock issued new, shares">27,084</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_d0_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndCommonWarrantMember_z4LNxuikPfz2" style="text-align: right" title="Stock issued new, value">411</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Common stock and Pre-Funded A.G.P. Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_d0_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndPreFundedAGPWarrantsMember_zPeEIihuZXwi" style="border-bottom: Black 1pt solid; text-align: right" title="Stock issued new, shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_d0_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndPreFundedAGPWarrantsMember_zpKXikxwDdZ7" style="border-bottom: Black 1pt solid; text-align: right" title="Stock issued new, value">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_d0_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndPreFundedAGPWarrantsMember_zUq6bpGcMvvb" style="border-bottom: Black 1pt solid; text-align: right" title="Stock issued new, shares">302,295</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_d0_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndPreFundedAGPWarrantsMember_zPj89Uqr6LEa" style="border-bottom: Black 1pt solid; text-align: right" title="Stock issued new, value">4,586</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--TotalCommonStockAndPrefundedWarrantsMember_zzrNGc87cAcb" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock issued new, shares">9,972,412</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--TotalCommonStockAndPrefundedWarrantsMember_zEkMNtVAW6F4" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock issued new, value">23,017</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--TotalCommonStockAndPrefundedWarrantsMember_zUr59CBYYLDl" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock issued new, shares">456,961</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--TotalCommonStockAndPrefundedWarrantsMember_zE6eRWzw09u1" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock issued new, value">14,030</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zXB5Cmsc4apk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock Options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2020, the Board of Directors of the Company approved the CNS Pharmaceuticals, Inc. 2020 Stock Plan (the “2020 Plan”). The 2020 Plan allows for the Board of Directors to grant various forms of incentive awards for up to four shares of common stock. The 2020 Plan was amended effective as of August 9, 2023, which was approved by the Company’s stockholders at the Company’s annual meeting on September 14, 2023. The amendment increased the 2020 Plan by <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20230808__20230809__us-gaap--PlanNameAxis__custom--Plan2020Member_zlk9giOBmkb5" title="Additional shares authorized under plan">25</span> shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 17, 2025, the Company held its scheduled 2025 Annual Meeting of Stockholders at which the Company’s stockholders approved amendments to the Company's 2020 Equity Plan including an increase in the number of shares of common stock authorized for issuance under the 2020 Plan by <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20251115__20261116__us-gaap--PlanNameAxis__custom--Plan2020Member_zltF2kDd2Xwi" title="Increase in shares authorized for issuance">114,916</span> shares. As amended, the number of shares of the common stock that may be issued under the 2020 Plan is <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20251117__us-gaap--PlanNameAxis__custom--Plan2020Member_ziN6fcM77l7k" title="Stock available for grant">115,061</span> shares (this includes the 114,916 share increase). As of June 30, 2026, there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260630__us-gaap--PlanNameAxis__custom--Plan2020Member_zgTwS7HBGokh" title="Shares available to issue">38,204</span> shares of common stock remaining to be issued under the 2020 Plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table summarizes the stock option activity for the six months ended June 30, 2026:</p> <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zt1tmMgHWWse" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Equity (Details - Option activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BE_zDmoAJtguSel" style="display: none">Schedule of stock option activity</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Options</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average Exercise Price Per Share</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 68%"><span style="font-size: 10pt">Outstanding, December 31, 2025</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zx3CuCU0DYbk" style="width: 13%; text-align: right" title="Options outstanding, beginning balance"><span style="font-size: 10pt">19,852</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQo43T2IuWyg" style="width: 13%; text-align: right" title="Weighted average exercise price per share outstanding, beginning balance"><span style="font-size: 10pt">2,737.78</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGlIxkuSxbv9" style="text-align: right" title="Options, granted"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zn3IrRJ5JoH6" style="text-align: right" title="Weighted average exercise price per share, granted"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Exercised</span></td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3tkI6GzFiYk" style="text-align: right" title="Options, exercised"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zf9YoI4mek25" style="text-align: right" title="Weighted average exercise price per share, exercised"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Forfeited</span></td> <td> </td> <td> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzaMTsa4y8s8" style="text-align: right" title="Options, forfeited"><span style="font-size: 10pt">(18</span></td> <td><span style="font-size: 10pt">)</span></td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1mjalYmMvwk" style="text-align: right" title="Weighted average exercise price per share, forfeited"><span style="font-size: 10pt">821,413.00</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Expired</span></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pip0_di0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFDOB2BmI9Lg" style="border-bottom: black 1pt solid; text-align: right" title="Options, expired"><span style="font-size: 10pt">(9,763</span></td> <td><span style="font-size: 10pt">) </span></td> <td> </td> <td style="padding-bottom: 1pt">$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhqzDc764cGe" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price per share, expired"><span style="font-size: 10pt">30.00</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Outstanding, June 30, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsb3Dk86OF5f" style="border-bottom: black 2.25pt double; text-align: right" title="Options outstanding, ending balance"><span style="font-size: 10pt">10,071</span></td> <td> </td> <td> </td> <td style="padding-bottom: 2.25pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4Hxb6TTM0K9" style="padding-bottom: 2.25pt; text-align: right" title="Weighted average exercise price per share outstanding, ending balance"><span style="font-size: 10pt">3,899.52</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Exercisable, June 30, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGxGETRl5Im9" style="border-bottom: black 2.25pt double; text-align: right" title="Options, exercisable"><span style="font-size: 10pt">5,057</span></td> <td> </td> <td> </td> <td style="padding-bottom: 2.25pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoxij2IhxB09" style="padding-bottom: 2.25pt; text-align: right" title="Weighted average exercise price per share, exercisable"><span style="font-size: 10pt">7,975.10</span></td> <td> </td></tr> </table> <p id="xdx_8A3_zvQZS71ZL0fi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2026, the outstanding stock options have a weighted average remaining term of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRnZaM9GDnud" title="Weighted average remaining term">9.37</span> years and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zH4dbuuQePv3" title="Aggregate intrinsic value">no</span> aggregate intrinsic value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock Warrants</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the stock warrant activity for the six months ended June 30, 2026:</p> <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zf9iLg2DC837" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Equity (Details - Warrant activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zENn1pqYjvwc" style="display: none">Schedule of stock warrant activity</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Warrants</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average Exercise Price Per Share</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 68%"><span style="font-size: 10pt">Outstanding, December 31, 2025</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zLpJsixEFhc8" style="width: 13%; text-align: right" title="Warrants outstanding at beginning"><span style="font-size: 10pt">333,931</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zKgeYeYPZrh6" style="width: 13%; text-align: right" title="Weighted-average exercise price per share at beginning"><span style="font-size: 10pt">90.75</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zhlwnKwpwiZf" style="text-align: right" title="Warrants granted"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zXNLucIa31R" style="text-align: right" title="Weighted-average exercise price per share granted"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Exercised</span></td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pip0_di0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zPc6ivFcLuRf" style="text-align: right" title="Warrants exercised"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zWOHxwMQmPb9" style="text-align: right" title="Weighted-average exercise price per share exercised"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Forfeited</span></td> <td> </td> <td> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pip0_di0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zghoqm0fi0Zb" style="text-align: right" title="Warrants forfeited"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_z677nZhT0Kce" style="text-align: right" title="Weighted-average exercise price per share forfeited"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Expired</span></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pip0_di0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zFmKBwAc9KWf" style="border-bottom: black 1pt solid; text-align: right" title="Warrants expired"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td style="padding-bottom: 1pt">$</td> <td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zI059c7LDi69" style="padding-bottom: 1pt; text-align: right" title="Weighted-average exercise price per share expired"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Outstanding, June 30, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_z32weEk1v33i" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding at ending"><span style="font-size: 10pt">333,931</span></td> <td> </td> <td> </td> <td style="padding-bottom: 2.25pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zv5URtXrH4z" style="padding-bottom: 2.25pt; text-align: right" title="Weighted-average exercise price per share at ending"><span style="font-size: 10pt">90.75</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Exercisable, June 30, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zMDInkDIZzT3" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants exercisable"><span style="font-size: 10pt">333,931</span></td> <td> </td> <td> </td> <td style="padding-bottom: 2.25pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_z268gHAndYl9" style="padding-bottom: 2.25pt; text-align: right" title="Weighted-average exercise price per share exercisable"><span style="font-size: 10pt">90.75</span></td> <td> </td></tr> </table> <p id="xdx_8A2_zmScKwKlUSg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2026, the outstanding and exercisable warrants have a weighted average remaining term of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zZCKUuzarSNl" title="Weighted average remaining term">3.86</span> years and had <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_z77lAifxa2S4" title="Aggregate intrinsic value">no</span> aggregate intrinsic value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Restricted Stock Units</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the RSUs activity for the six months ended June 30, 2026:</p> <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zasW1BMAC4gb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Equity (Details - Restricted stock units activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BC_zo9ZjoUNIEb7" style="display: none">Schedule of RSUs activity</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>RSUs</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average Grant Date Fair Value</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 68%"><span style="font-size: 10pt">Non-vested, December 31, 2025</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4qklVzXrDI4" style="width: 13%; text-align: right" title="Non-vested at beginning"><span style="font-size: 10pt">17</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zi87nWg9K1M1" style="width: 13%; text-align: right" title="Weighted-average grant date fair value non-vested at beginning"><span style="font-size: 10pt">93,902.82</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIiJX6v6Rxxh" style="text-align: right" title="RSUs granted"><span style="font-size: 10pt">57,000</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGWLcbOUdYq5" style="text-align: right" title="Weighted average grant date fair value granted"><span style="font-size: 10pt">3.13</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Vested</span></td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pip0_di0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8X8SrpJJ4Ck" style="text-align: right" title="RSUs vested"><span style="font-size: 10pt">(10</span></td> <td><span style="font-size: 10pt">)</span></td> <td> </td> <td>$</td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziNSnYMRttX8" style="text-align: right" title="Weighted-average grant date fair value vested"><span style="font-size: 10pt">66,643.20</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Forfeited</span></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pip0_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zegjODhd8wI4" style="border-bottom: black 1pt solid; text-align: right" title="RSUs forfeited"><span style="font-size: 10pt">(7</span></td> <td><span style="font-size: 10pt">)</span></td> <td> </td> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z52xiKSmQQ65" style="padding-bottom: 1pt; text-align: right" title="Weighted-average grant date fair value forfeited"><span style="font-size: 10pt">133,273.71</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Non-vested, June 30, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh8zPAyMIjw8" style="border-bottom: black 2.25pt double; text-align: right" title="Non-vested at endning"><span style="font-size: 10pt">57,000</span></td> <td> </td> <td> </td> <td style="padding-bottom: 2.25pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhDNywPR2vf1" style="padding-bottom: 2.25pt; text-align: right" title="Weighted-average grant date fair value non-vested at ending"><span style="font-size: 10pt">3.13</span></td> <td> </td></tr> </table> <p id="xdx_8A6_zXqbAsHvkPJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Performance Units</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table summarizes the PUs activity for the six months ended June 30, 2026:</p> <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zU83SSFoPfya" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Equity (Details - Performance units activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B5_zdE0I1gIFtuj" style="display: none">Schedule of PUs activity</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>PUs</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average Grant Date Fair Value</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 68%"><span style="font-size: 10pt">Non-vested – December 31, 2025</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zY7zdAjDT3H4" style="width: 13%; text-align: right" title="Non-vested at beginning"><span style="font-size: 10pt">4</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_z6HSwHjbg0C3" style="width: 13%; text-align: right" title="Weighted-average grant date fair value non-vested at beginning"><span style="font-size: 10pt">117,000.00</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zCGUI4mJsQtc" style="text-align: right" title="PUs granted"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zx3wfR6BA7M3" style="text-align: right" title="Weighted average grant date fair value granted"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Vested</span></td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zqyAT9OKpf2h" style="text-align: right" title="PUs vested"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zcgKGQUJb326" style="text-align: right" title="Weighted average grant date fair value vested"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Forfeited/Cancelled</span></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zKFy81hbcG9d" style="border-bottom: black 1pt solid; text-align: right" title="PUs forfeited/cancelled"><span style="font-size: 10pt">(4</span></td> <td><span style="font-size: 10pt">)</span></td> <td> </td> <td style="padding-bottom: 1pt">$</td> <td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zJPdygNawoe" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value forfeited/cancelled"><span style="font-size: 10pt">117,000.00</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Non-vested, June 30, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zOTgY9zdGT5i" style="border-bottom: black 2.25pt double; text-align: right" title="Non-vested at endning"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td style="padding-bottom: 2.25pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zQaH3Xswk0zl" style="padding-bottom: 2.25pt; text-align: right" title="Weighted-average grant date fair value non-vested at ending"><span style="font-size: 10pt">–</span></td> <td> </td></tr> </table> <p id="xdx_8A6_zxnGekTz9ry9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock-Based Compensation Expense</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes stock-based compensation expense for the six months ended June 30, 2026 (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_pn3n3_zx41OHjBvR8i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details - Stock based compensation expense)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BA_zb25MioZgoE5" style="display: none">Schedule of stock based compensation</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensation_c20260401__20260630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z82F1YiGbKYj" title="Stock-based compensation expense">(8</span></td><td style="width: 1%; text-align: left">) </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensation_c20250401__20250630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zK1aDBNqkTTe" title="Stock-based compensation expense">8</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensation_c20260101__20260630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvPfRXjJCJTk" title="Stock-based compensation expense">(20</span></td><td style="width: 1%; text-align: left">) </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensation_c20250101__20250630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqx5w8fsWBUj" title="Stock-based compensation expense">53</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">RSUs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensation_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zensd9yteai5" title="Stock-based compensation expense">10</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIpQQpNaBuif" title="Stock-based compensation expense">14</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensation_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zntNXIGyCcrb" title="Stock-based compensation expense">25</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensation_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuscEwTaJyba" title="Stock-based compensation expense">31</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensation_c20260401__20260630_ztJIhMRYwyh3" title="Stock-based compensation expense">2</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensation_c20250401__20250630_zhdd2S6m5erg" title="Stock-based compensation expense">22</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensation_c20260101__20260630_zj3wKqZgu5Dd" title="Stock-based compensation expense">5</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensation_c20250101__20250630_zMjSCQIb9eEa" title="Stock-based compensation expense">84</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_8AD_zkWWcfbmYujk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2026, the Company had $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zi0rQSLeQJPk" title="Unrecognized stock-based compensation expense">0.2</span> million of unrecognized stock-based compensation expense related primarily to outstanding RSUs. The Company did <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_do_c20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zO1qjPVCwWP" title="Unrecognized stock-based compensation expense">no</span>t have any unrecognized expense related to PUs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> 300000000 0.001 5000000 0.001 1-for-12 300000000 25000000 5000000 416667 25000000 300000000 416667 5000000 650000 9143479 22500000 20700000 0 27084 302295 329381 <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfProductWarrantyLiabilityTableTextBlock_pn3n3_zOGBKlbMDaA8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details - Pre-funded warrant activity)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BB_zfIdmGxNC6Wg" style="display: none">Schedule of pre funded warrant activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 32%; text-align: left">Purchase Agreement</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20260101__20260630__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zJuMI51Wpl3h" style="width: 13%; text-align: right" title="Stock issued new, shares">650,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20260101__20260630__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zfi3WA7DyvZf" style="width: 13%; text-align: right" title="Stock issued new, value">1,495</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_d0_c20250101__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zdZxeQd5Ilfk" style="width: 13%; text-align: right" title="Stock issued new, shares">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_d0_c20250101__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zV3ZZkFrgc0l" style="width: 13%; text-align: right" title="Stock issued new, value">–</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Pre-Funded Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_z2kvHWihHHNa" style="text-align: right">9,143,479</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zoum93O3ukIj" style="text-align: right">21,021</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zqiyiMBp0Z33" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552">–</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_z3qPQz239dyc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0553">–</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">AGP ATM Sales Agreement</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20260101__20260630__us-gaap--SubsidiarySaleOfStockAxis__custom--AGPATMSalesAgreementMember_z3mazfSxVyP8" style="text-align: right" title="Stock issued new, shares">178,933</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20260101__20260630__us-gaap--SubsidiarySaleOfStockAxis__custom--AGPATMSalesAgreementMember_zMBSVU6w89F7" style="text-align: right" title="Stock issued new, shares">501</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20250101__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--AGPATMSalesAgreementMember_zQT2Vc0vowI6" style="text-align: right" title="Stock issued new, shares">127,582</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250101__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--AGPATMSalesAgreementMember_zHBfoMCv5xG9" style="text-align: right" title="Stock issued new, shares">9,033</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Common stock and Common Warrant</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_d0_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndCommonWarrantMember_zyOayAuK8Lnd" style="text-align: right" title="Stock issued new, shares">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_d0_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndCommonWarrantMember_z1Bu5GiKcNC5" style="text-align: right" title="Stock issued new, value">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_d0_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndCommonWarrantMember_zdsUqN2Bq9v5" style="text-align: right" title="Stock issued new, shares">27,084</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_d0_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndCommonWarrantMember_z4LNxuikPfz2" style="text-align: right" title="Stock issued new, value">411</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Common stock and Pre-Funded A.G.P. Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_d0_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndPreFundedAGPWarrantsMember_zPeEIihuZXwi" style="border-bottom: Black 1pt solid; text-align: right" title="Stock issued new, shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_d0_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndPreFundedAGPWarrantsMember_zpKXikxwDdZ7" style="border-bottom: Black 1pt solid; text-align: right" title="Stock issued new, value">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_d0_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndPreFundedAGPWarrantsMember_zUq6bpGcMvvb" style="border-bottom: Black 1pt solid; text-align: right" title="Stock issued new, shares">302,295</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_d0_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndPreFundedAGPWarrantsMember_zPj89Uqr6LEa" style="border-bottom: Black 1pt solid; text-align: right" title="Stock issued new, value">4,586</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--TotalCommonStockAndPrefundedWarrantsMember_zzrNGc87cAcb" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock issued new, shares">9,972,412</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--TotalCommonStockAndPrefundedWarrantsMember_zEkMNtVAW6F4" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock issued new, value">23,017</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--TotalCommonStockAndPrefundedWarrantsMember_zUr59CBYYLDl" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock issued new, shares">456,961</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250101__20250630__us-gaap--StatementClassOfStockAxis__custom--TotalCommonStockAndPrefundedWarrantsMember_zE6eRWzw09u1" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock issued new, value">14,030</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 650000 1495000 0 0 9143479 21021000 178933 501000 127582 9033000 0 0 27084 411000 0 0 302295 4586000 9972412 23017000 456961 14030000 25 114916 115061 38204 <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zt1tmMgHWWse" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Equity (Details - Option activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BE_zDmoAJtguSel" style="display: none">Schedule of stock option activity</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Options</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average Exercise Price Per Share</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 68%"><span style="font-size: 10pt">Outstanding, December 31, 2025</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zx3CuCU0DYbk" style="width: 13%; text-align: right" title="Options outstanding, beginning balance"><span style="font-size: 10pt">19,852</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQo43T2IuWyg" style="width: 13%; text-align: right" title="Weighted average exercise price per share outstanding, beginning balance"><span style="font-size: 10pt">2,737.78</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGlIxkuSxbv9" style="text-align: right" title="Options, granted"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zn3IrRJ5JoH6" style="text-align: right" title="Weighted average exercise price per share, granted"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Exercised</span></td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3tkI6GzFiYk" style="text-align: right" title="Options, exercised"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zf9YoI4mek25" style="text-align: right" title="Weighted average exercise price per share, exercised"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Forfeited</span></td> <td> </td> <td> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzaMTsa4y8s8" style="text-align: right" title="Options, forfeited"><span style="font-size: 10pt">(18</span></td> <td><span style="font-size: 10pt">)</span></td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1mjalYmMvwk" style="text-align: right" title="Weighted average exercise price per share, forfeited"><span style="font-size: 10pt">821,413.00</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Expired</span></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pip0_di0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFDOB2BmI9Lg" style="border-bottom: black 1pt solid; text-align: right" title="Options, expired"><span style="font-size: 10pt">(9,763</span></td> <td><span style="font-size: 10pt">) </span></td> <td> </td> <td style="padding-bottom: 1pt">$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhqzDc764cGe" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price per share, expired"><span style="font-size: 10pt">30.00</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Outstanding, June 30, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsb3Dk86OF5f" style="border-bottom: black 2.25pt double; text-align: right" title="Options outstanding, ending balance"><span style="font-size: 10pt">10,071</span></td> <td> </td> <td> </td> <td style="padding-bottom: 2.25pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4Hxb6TTM0K9" style="padding-bottom: 2.25pt; text-align: right" title="Weighted average exercise price per share outstanding, ending balance"><span style="font-size: 10pt">3,899.52</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Exercisable, June 30, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGxGETRl5Im9" style="border-bottom: black 2.25pt double; text-align: right" title="Options, exercisable"><span style="font-size: 10pt">5,057</span></td> <td> </td> <td> </td> <td style="padding-bottom: 2.25pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoxij2IhxB09" style="padding-bottom: 2.25pt; text-align: right" title="Weighted average exercise price per share, exercisable"><span style="font-size: 10pt">7,975.10</span></td> <td> </td></tr> </table> 19852 2737.78 0 0 0 0 18 821413.00 9763 30.00 10071 3899.52 5057 7975.10 P9Y4M13D 0 <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zf9iLg2DC837" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Equity (Details - Warrant activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zENn1pqYjvwc" style="display: none">Schedule of stock warrant activity</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Warrants</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average Exercise Price Per Share</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 68%"><span style="font-size: 10pt">Outstanding, December 31, 2025</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zLpJsixEFhc8" style="width: 13%; text-align: right" title="Warrants outstanding at beginning"><span style="font-size: 10pt">333,931</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zKgeYeYPZrh6" style="width: 13%; text-align: right" title="Weighted-average exercise price per share at beginning"><span style="font-size: 10pt">90.75</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zhlwnKwpwiZf" style="text-align: right" title="Warrants granted"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zXNLucIa31R" style="text-align: right" title="Weighted-average exercise price per share granted"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Exercised</span></td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pip0_di0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zPc6ivFcLuRf" style="text-align: right" title="Warrants exercised"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zWOHxwMQmPb9" style="text-align: right" title="Weighted-average exercise price per share exercised"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Forfeited</span></td> <td> </td> <td> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pip0_di0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zghoqm0fi0Zb" style="text-align: right" title="Warrants forfeited"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_z677nZhT0Kce" style="text-align: right" title="Weighted-average exercise price per share forfeited"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Expired</span></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pip0_di0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zFmKBwAc9KWf" style="border-bottom: black 1pt solid; text-align: right" title="Warrants expired"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td style="padding-bottom: 1pt">$</td> <td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zI059c7LDi69" style="padding-bottom: 1pt; text-align: right" title="Weighted-average exercise price per share expired"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Outstanding, June 30, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_z32weEk1v33i" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding at ending"><span style="font-size: 10pt">333,931</span></td> <td> </td> <td> </td> <td style="padding-bottom: 2.25pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zv5URtXrH4z" style="padding-bottom: 2.25pt; text-align: right" title="Weighted-average exercise price per share at ending"><span style="font-size: 10pt">90.75</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Exercisable, June 30, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zMDInkDIZzT3" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants exercisable"><span style="font-size: 10pt">333,931</span></td> <td> </td> <td> </td> <td style="padding-bottom: 2.25pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20260630__us-gaap--AwardTypeAxis__custom--WarrantsMember_z268gHAndYl9" style="padding-bottom: 2.25pt; text-align: right" title="Weighted-average exercise price per share exercisable"><span style="font-size: 10pt">90.75</span></td> <td> </td></tr> </table> 333931 90.75 0 0 -0 0 -0 0 -0 0 333931 90.75 333931 90.75 P3Y10M9D 0 <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zasW1BMAC4gb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Equity (Details - Restricted stock units activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BC_zo9ZjoUNIEb7" style="display: none">Schedule of RSUs activity</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>RSUs</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average Grant Date Fair Value</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 68%"><span style="font-size: 10pt">Non-vested, December 31, 2025</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4qklVzXrDI4" style="width: 13%; text-align: right" title="Non-vested at beginning"><span style="font-size: 10pt">17</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zi87nWg9K1M1" style="width: 13%; text-align: right" title="Weighted-average grant date fair value non-vested at beginning"><span style="font-size: 10pt">93,902.82</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIiJX6v6Rxxh" style="text-align: right" title="RSUs granted"><span style="font-size: 10pt">57,000</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGWLcbOUdYq5" style="text-align: right" title="Weighted average grant date fair value granted"><span style="font-size: 10pt">3.13</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Vested</span></td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pip0_di0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8X8SrpJJ4Ck" style="text-align: right" title="RSUs vested"><span style="font-size: 10pt">(10</span></td> <td><span style="font-size: 10pt">)</span></td> <td> </td> <td>$</td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziNSnYMRttX8" style="text-align: right" title="Weighted-average grant date fair value vested"><span style="font-size: 10pt">66,643.20</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Forfeited</span></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pip0_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zegjODhd8wI4" style="border-bottom: black 1pt solid; text-align: right" title="RSUs forfeited"><span style="font-size: 10pt">(7</span></td> <td><span style="font-size: 10pt">)</span></td> <td> </td> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z52xiKSmQQ65" style="padding-bottom: 1pt; text-align: right" title="Weighted-average grant date fair value forfeited"><span style="font-size: 10pt">133,273.71</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Non-vested, June 30, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh8zPAyMIjw8" style="border-bottom: black 2.25pt double; text-align: right" title="Non-vested at endning"><span style="font-size: 10pt">57,000</span></td> <td> </td> <td> </td> <td style="padding-bottom: 2.25pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhDNywPR2vf1" style="padding-bottom: 2.25pt; text-align: right" title="Weighted-average grant date fair value non-vested at ending"><span style="font-size: 10pt">3.13</span></td> <td> </td></tr> </table> 17 93902.82 57000 3.13 10 66643.20 7 133273.71 57000 3.13 <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zU83SSFoPfya" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Equity (Details - Performance units activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B5_zdE0I1gIFtuj" style="display: none">Schedule of PUs activity</span></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>PUs</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average Grant Date Fair Value</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 68%"><span style="font-size: 10pt">Non-vested – December 31, 2025</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zY7zdAjDT3H4" style="width: 13%; text-align: right" title="Non-vested at beginning"><span style="font-size: 10pt">4</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_z6HSwHjbg0C3" style="width: 13%; text-align: right" title="Weighted-average grant date fair value non-vested at beginning"><span style="font-size: 10pt">117,000.00</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Granted</span></td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zCGUI4mJsQtc" style="text-align: right" title="PUs granted"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zx3wfR6BA7M3" style="text-align: right" title="Weighted average grant date fair value granted"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Vested</span></td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zqyAT9OKpf2h" style="text-align: right" title="PUs vested"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zcgKGQUJb326" style="text-align: right" title="Weighted average grant date fair value vested"><span style="font-size: 10pt">–</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Forfeited/Cancelled</span></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zKFy81hbcG9d" style="border-bottom: black 1pt solid; text-align: right" title="PUs forfeited/cancelled"><span style="font-size: 10pt">(4</span></td> <td><span style="font-size: 10pt">)</span></td> <td> </td> <td style="padding-bottom: 1pt">$</td> <td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zJPdygNawoe" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value forfeited/cancelled"><span style="font-size: 10pt">117,000.00</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td><span style="font-size: 10pt">Non-vested, June 30, 2026</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zOTgY9zdGT5i" style="border-bottom: black 2.25pt double; text-align: right" title="Non-vested at endning"><span style="font-size: 10pt">–</span></td> <td> </td> <td> </td> <td style="padding-bottom: 2.25pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_d0_c20260101__20260630__us-gaap--AwardTypeAxis__custom--PerformanceUnitsMember_zQaH3Xswk0zl" style="padding-bottom: 2.25pt; text-align: right" title="Weighted-average grant date fair value non-vested at ending"><span style="font-size: 10pt">–</span></td> <td> </td></tr> </table> 4 117000.00 0 0 -0 0 4000 117000.00 0 0 <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock_pn3n3_zx41OHjBvR8i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details - Stock based compensation expense)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BA_zb25MioZgoE5" style="display: none">Schedule of stock based compensation</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensation_c20260401__20260630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z82F1YiGbKYj" title="Stock-based compensation expense">(8</span></td><td style="width: 1%; text-align: left">) </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensation_c20250401__20250630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zK1aDBNqkTTe" title="Stock-based compensation expense">8</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensation_c20260101__20260630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvPfRXjJCJTk" title="Stock-based compensation expense">(20</span></td><td style="width: 1%; text-align: left">) </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensation_c20250101__20250630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqx5w8fsWBUj" title="Stock-based compensation expense">53</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">RSUs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensation_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zensd9yteai5" title="Stock-based compensation expense">10</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIpQQpNaBuif" title="Stock-based compensation expense">14</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensation_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zntNXIGyCcrb" title="Stock-based compensation expense">25</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensation_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuscEwTaJyba" title="Stock-based compensation expense">31</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensation_c20260401__20260630_ztJIhMRYwyh3" title="Stock-based compensation expense">2</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensation_c20250401__20250630_zhdd2S6m5erg" title="Stock-based compensation expense">22</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensation_c20260101__20260630_zj3wKqZgu5Dd" title="Stock-based compensation expense">5</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensation_c20250101__20250630_zMjSCQIb9eEa" title="Stock-based compensation expense">84</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> -8000 8000 -20000 53000 10000 14000 25000 31000 2000 22000 5000 84000 200000 0 <p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z8XhyxGgJcTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 5 – <span id="xdx_824_zYo3oJpW61fe">Commitments and Contingencies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Executive Employment Agreements</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 16, 2025, John Climaco resigned from his positions as chief executive officer of the Company and as a member of the Company’s Board of Directors. The Company and Mr. Climaco entered into a Separation and Severance Agreement dated as of December 16, 2025 (the “Separation Agreement”), which memorializes the terms of his resignation and separation from service with the Company. Pursuant to the Separation Agreement, subject to Mr. Climaco’s timely execution, non-revocation, and compliance with the agreement’s terms, the Company is providing severance benefits, including (i) severance equal to twelve months of Mr. Climaco’s current annualized base salary, paid in twelve equal monthly installments, and payment of his base salary through December 31, 2025; (ii) payment of Mr. Climaco’s 2025 cash bonus in the total amount of $<span id="xdx_904_eus-gaap--AccruedBonusesCurrent_iI_c20251216__us-gaap--RelatedPartyTransactionAxis__custom--MrClimacoMember_zWLwB5s5Ulg7" title="Cash bonus">319,000</span>, paid in twelve equal monthly installments; and (iii) payment by the Company of the employer portion of premiums for Mr. Climaco’s continued group medical coverage under COBRA for twelve months following the Separation Date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Reata Agreement</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 21, 2017, the Company entered into a Collaboration and Asset Purchase Agreement with Reata Pharmaceuticals, Inc. (“Reata”). Through this agreement, the Company purchased all of Reata’s rights, title, interest and previously conducted research and development results in the chemical compound commonly known as Berubicin. In exchange for these rights, the Company agreed to pay Reata an amount equal to 2.25% of the net sales of Berubicin for a period of 10 years from the Company’s first commercial sale of Berubicin plus $<span id="xdx_90B_ecustom--CollaborativeArrangementConsiderationExchangedAmount_iI_c20171121__us-gaap--RelatedPartyTransactionAxis__custom--ReataAgreementMember_zIqUytUqkPa5" title="Collaborative arrangement consideration exchanged amount">10,000</span>. Reata also agreed to collaborate with the Company on the development of Berubicin, from time to time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cortice Biosciences, Inc. Exclusive License Agreement</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 29, 2024, the Company entered into an Exclusive License Agreement (the “Cortice Agreements”) with Cortice Biosciences, Inc. (“Cortice”) pursuant to which Cortice granted the Company an exclusive license to the intellectual property rights related to certain patents around the compound TPI 287 in the United States, Canada, Mexico and Japan. The term of the license will expire, other than due to a breach of the Cortice Agreements, at the end of the royalty term with respect to any licensed product in any of the included territories, which begins upon the first commercial sale in such territory and ends on the latest of (i) ten years after such sale, (ii) the expiration of regulatory or marketing exclusivity for such licensed product in such country, or (iii) the expiration of the last to expire valid patent claim in such country covering such licensed product. Pursuant to the Cortice Agreements, the Company agreed to issue Cortice <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240728__20240729__us-gaap--SubsidiarySaleOfStockAxis__custom--CorticeAgreementsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TransactionTypeAxis__custom--ClosingOfTheTransactionMember_zgrcS0ZRPsa3" title="Number of shares issued during transaction">956</span> shares of the Company’s common stock upon the closing of the transaction, which occurred on July 29, 2024, and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240728__20240729__us-gaap--SubsidiarySaleOfStockAxis__custom--CorticeAgreementsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TransactionTypeAxis__custom--NasdaqRequiredShareholderApprovalMember_zNIlccK14Vt3" title="Number of shares issued during transaction">73</span> shares of Company common stock upon the receipt of shareholder approval of such issuance as required by the rules of the Nasdaq Stock Market. The Company also agreed to make milestone payments to Cortice in either cash or shares of Company common stock (at Cortice’s option) upon: (i) meeting the primary endpoint of a pivotal trial for a licensed product – either $15.0 million or 686 shares of Company common stock; (ii) FDA acceptance of a New Drug Application for a licensed product – either $30.0 million or 1,371 shares of Company common stock; (iii) the first commercial sale in the United States of a licensed product – either $45.0 million or 2,056 shares of Company common stock; and (iv) the first commercial sale in Japan of a licensed product – either $10.0 million or 343 shares of Company common stock. The Company’s obligation to pay the above milestones in Company common stock is subject to the receipt of shareholder approval as required by the rules of the Nasdaq Stock Market. The Company also agreed to pay Cortice royalties on sales of licensed products of between 3.0%-7.5%. Finally, to the extent Cortice is required to pay any milestone payments to the original holder of the intellectual property rights licensed, the Company has agreed to make such payments to Cortice. As of June 30, 2026, there were no accruals related to the milestone payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 319000 10000 956 73 <p id="xdx_806_eus-gaap--EarningsPerShareTextBlock_zuWDImb9pAF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 6 – <span id="xdx_82D_zcizGcVktZDi">Earnings Per Share</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following potentially dilutive securities have been excluded from the diluted per share calculations as they would be anti-dilutive:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zL8EEqglNKSi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings Per Share (Details - Anti-dilutive shares)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BD_z40foRK7cQCl" style="display: none">Schedule of anti-dilutive shares</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 32%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zIflVFEJLc6" style="width: 13%; text-align: right" title="Anti-dilutive shares">333,931</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCCUsKZYITwe" style="width: 13%; text-align: right" title="Anti-dilutive shares">404,747</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zK9Vysg3qc7i" style="width: 13%; text-align: right" title="Anti-dilutive shares">333,931</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYP81UTTVyt2" style="width: 13%; text-align: right" title="Anti-dilutive shares">404,747</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>RSUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCiCQevPn889" style="text-align: right" title="Anti-dilutive shares">57,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIjnDpzUUTo4" style="text-align: right" title="Anti-dilutive shares">18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAf3IWr0Lrqg" style="text-align: right" title="Anti-dilutive shares">57,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBKl2cYAhMAj" style="text-align: right" title="Anti-dilutive shares">18</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQ82EYXRP0Xe" style="text-align: right" title="Anti-dilutive shares">10,071</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPCaTfPOlASh" style="text-align: right" title="Anti-dilutive shares">70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfyjc4gghPS2" style="text-align: right" title="Anti-dilutive shares">10,071</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjUFtHBf7O1" style="text-align: right" title="Anti-dilutive shares">70</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>PUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zpINES2uG9E4" style="text-align: right" title="Anti-dilutive shares">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zwMRpW2pk2X1" style="text-align: right" title="Anti-dilutive shares">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zjDlc2NCcnf3" style="text-align: right" title="Anti-dilutive shares">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ze27ys5dWZ91" style="text-align: right" title="Anti-dilutive shares">5</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_zFi6sAd6sTp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Outstanding pre-funded warrants as of June 30, 2026 are <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zbgNy3o873Xb" title="Warrants outstanding, shares">9,143,479</span>. Pre-funded warrants are considered outstanding as of their issuance date and are included in basic and diluted net loss per share because they are fully vested and exercisable for nominal cash consideration.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zL8EEqglNKSi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings Per Share (Details - Anti-dilutive shares)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BD_z40foRK7cQCl" style="display: none">Schedule of anti-dilutive shares</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 32%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zIflVFEJLc6" style="width: 13%; text-align: right" title="Anti-dilutive shares">333,931</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCCUsKZYITwe" style="width: 13%; text-align: right" title="Anti-dilutive shares">404,747</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zK9Vysg3qc7i" style="width: 13%; text-align: right" title="Anti-dilutive shares">333,931</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYP81UTTVyt2" style="width: 13%; text-align: right" title="Anti-dilutive shares">404,747</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>RSUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCiCQevPn889" style="text-align: right" title="Anti-dilutive shares">57,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIjnDpzUUTo4" style="text-align: right" title="Anti-dilutive shares">18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAf3IWr0Lrqg" style="text-align: right" title="Anti-dilutive shares">57,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBKl2cYAhMAj" style="text-align: right" title="Anti-dilutive shares">18</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQ82EYXRP0Xe" style="text-align: right" title="Anti-dilutive shares">10,071</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPCaTfPOlASh" style="text-align: right" title="Anti-dilutive shares">70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfyjc4gghPS2" style="text-align: right" title="Anti-dilutive shares">10,071</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjUFtHBf7O1" style="text-align: right" title="Anti-dilutive shares">70</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>PUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zpINES2uG9E4" style="text-align: right" title="Anti-dilutive shares">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zwMRpW2pk2X1" style="text-align: right" title="Anti-dilutive shares">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zjDlc2NCcnf3" style="text-align: right" title="Anti-dilutive shares">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ze27ys5dWZ91" style="text-align: right" title="Anti-dilutive shares">5</td><td style="text-align: left"> </td></tr> </table> 333931000 404747000 333931000 404747000 57000000 18000 57000000 18000 10071000 70000 10071000 70000 0 5000 0 5000 9143479 <p id="xdx_80E_eus-gaap--FairValueDisclosuresTextBlock_zobeydaAFIM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 7 – <span id="xdx_829_z160HL3c2f8d">Fair Value Measurements </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents information about our financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_pn3n3_zpbI9znT2tUb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details - Fair value measurements)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zVWJbX1oNhRg" style="display: none">Schedule of fair value measurements</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank deposit account</p></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--CashAndCashEquivalentsAxis__custom--BankDepositAccountMember_zTJmc8tSOJCf" style="width: 11%; text-align: right" title="Financial instruments owned at fair value">19,920</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__custom--BankDepositAccountMember_zsW7ZKbE7B95" style="width: 11%; text-align: right">19,920</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__custom--BankDepositAccountMember_zclF4HBseBQ5" style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zOSw58ymk24" style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%">Assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank deposit account</p></td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--CashAndCashEquivalentsAxis__custom--BankDepositAccountMember_zJ3ISbQY0St3" style="text-align: right" title="Money Market">6,642</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__custom--BankDepositAccountMember_zQtDYG5rhsw1" style="text-align: right" title="Money Market">6,642</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__custom--BankDepositAccountMember_zZ48Zcncwl3a" style="text-align: right" title="Money Market">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__custom--BankDepositAccountMember_zv0myyixLEsd" style="text-align: right" title="Money Market">–</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_8A8_z4tcxpYssS7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank deposit accounts are included within cash and cash equivalents in the accompanying balance sheets and are recognized at fair value. As of June 30, 2026 and December 31, 2025, the Company only held Level 1 financial instruments and there were <span id="xdx_907_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_do_c20260630_zdWKzLrO5kZ4" title="Financial instruments owned at fair value"><span id="xdx_909_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_do_c20251231_zLeTHthertB8" title="Financial instruments owned at fair value">no</span></span> transfers among levels.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_pn3n3_zpbI9znT2tUb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details - Fair value measurements)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zVWJbX1oNhRg" style="display: none">Schedule of fair value measurements</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank deposit account</p></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--CashAndCashEquivalentsAxis__custom--BankDepositAccountMember_zTJmc8tSOJCf" style="width: 11%; text-align: right" title="Financial instruments owned at fair value">19,920</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__custom--BankDepositAccountMember_zsW7ZKbE7B95" style="width: 11%; text-align: right">19,920</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__custom--BankDepositAccountMember_zclF4HBseBQ5" style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zOSw58ymk24" style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%">Assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank deposit account</p></td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--CashAndCashEquivalentsAxis__custom--BankDepositAccountMember_zJ3ISbQY0St3" style="text-align: right" title="Money Market">6,642</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--CashAndCashEquivalentsAxis__custom--BankDepositAccountMember_zQtDYG5rhsw1" style="text-align: right" title="Money Market">6,642</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--CashAndCashEquivalentsAxis__custom--BankDepositAccountMember_zZ48Zcncwl3a" style="text-align: right" title="Money Market">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--CashAndCashEquivalentsAxis__custom--BankDepositAccountMember_zv0myyixLEsd" style="text-align: right" title="Money Market">–</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> 19920000 19920000 0 0 6642000 6642000 0 0 0 0 <p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_z54JtEynqJj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 8 – <span id="xdx_826_zbCnfrbLJdF1">Subsequent Events </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 11, 2026, Michal Fisher was nominated and appointed to serve as a member of our Compensation Committee. Ms. Fisher was appointed to our Board of Directors on May 4, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> false false false false